Telemedicine, ADHD, and the 2020 Guidelines: What Indian Psychiatrists Can and Cannot Do Remotely

The Telemedicine Practice Guidelines, 2020 were notified during the early phase of the COVID-19 pandemic. Until then, Indian medical regulation had very little to say about the question of whether a registered medical practitioner could lawfully consult, diagnose, and prescribe to a patient by phone or video. The 2020 Guidelines settled the basics. They also created the regulatory frame in which Indian ADHD care now sits.

This is an explainer of how the Guidelines work, what they say about ADHD medication specifically, and why most Indian psychiatrists treat stimulant prescriptions as something that requires an in-person visit.

What the 2020 Guidelines do

The Telemedicine Practice Guidelines, 2020 were issued under the framework of the Indian Medical Council Act and the Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002. They establish:

• That registered medical practitioners can lawfully provide tele-consultation under defined conditions.
• That the doctor-patient relationship in a tele-consultation is the same as in an in-person consultation in terms of professional duties.
• A categorisation of medicines into List O, List A, List B, and a prohibited list, with progressively stricter conditions for prescription by tele-consultation.
• Identity verification requirements, consent requirements, record-keeping requirements, and prohibitions on certain types of practice (for example, the Guidelines prohibit prescription of medicines listed in Schedule X of the Drugs and Cosmetics Rules and substances listed under the Narcotic Drugs and Psychotropic Substances Act, 1985).

The four lists

The medicine categorisation is the part most relevant for ADHD:

• List O includes medicines that are over-the-counter or that are typically used for minor self-limiting conditions. These can be prescribed at any tele-consultation.
• List A includes medicines that may be prescribed at a first tele-consultation. The list is meant to cover commonly used medicines for routine conditions.
• List B includes medicines that may be prescribed at a follow-up tele-consultation, where the patient was previously seen in person for the same condition by the same registered medical practitioner.
• The prohibited list includes medicines that may not be prescribed by tele-consultation at all. This list includes medicines listed in Schedule X of the Drugs and Cosmetics Rules and substances under the NDPS Act schedules.

Where ADHD medications fall

Atomoxetine, the principal non-stimulant ADHD medication used in Indian practice, is dispensed under Schedule H. It is generally treated as prescribable by tele-consultation under the framework of the Guidelines, subject to the doctor-patient relationship being properly established and the consultation meeting the other requirements.

Methylphenidate, the principal stimulant ADHD medication used in Indian practice, sits under both Schedule X of the Drugs and Cosmetics Rules and the schedules under the NDPS Act. Methylphenidate falls within the prohibited list for purposes of the Telemedicine Practice Guidelines. It cannot be lawfully prescribed by tele-consultation.

That single legal fact accounts for a large part of how Indian psychiatry actually delivers ADHD care today.

The cautious clinical interpretation

Many Indian psychiatrists practising in the post-2020 environment have settled into a pattern that tries to honour both the Guidelines and the practical reality of chronic ADHD care:

• Initial evaluation and diagnosis can often be done by tele-consultation, particularly for adult patients where the clinical picture is not complex.
• Non-stimulant pharmacotherapy (atomoxetine, off-label bupropion, off-label clonidine and similar) is initiated and titrated by tele-consultation where appropriate.
• Stimulant pharmacotherapy is generally initiated only after an in-person consultation. Subsequent stimulant prescriptions are also generally written in-person, because the prohibition is not waived for follow-ups.
• Patients in remote areas or at substantial distance from the psychiatrist often end up with hybrid models: in-person initial consultation, in-person stimulant prescriptions, tele-follow-ups for non-stimulant management and behavioural support.

This is not a position prescribed by the Guidelines themselves. It is the clinical and legal interpretation that has emerged from the post-2020 environment. Different psychiatrists draw the lines slightly differently.

Identity, consent, and records

The Guidelines impose several procedural requirements that affect the patient experience:

• Identity verification: the practitioner is responsible for verifying patient identity, and the patient is responsible for verifying the practitioner’s identity (by checking the registration number with the National Medical Commission’s Indian Medical Register or the relevant State Medical Council register).
• Informed consent: the patient must consent to the tele-consultation. Consent can be implied (initiating the call) for adults, but explicit consent is appropriate for sensitive consultations and for minors through a parent or guardian.
• Record-keeping: the practitioner must maintain records of the consultation, prescription, and any data shared. The Digital Personal Data Protection Act, 2023 sits on top of this with its own data-handling requirements.

What remains unsettled

A few corners of the regulatory landscape are not cleanly resolved:

• The 2020 Guidelines were notified during a pandemic and have not been comprehensively updated for chronic outpatient psychiatric care.
• The prohibition on stimulant prescription does not distinguish between initiating treatment and continuing established treatment for a stable patient. Whether that distinction should be drawn in a future update is a topic of professional and academic discussion.
• The interaction between the Guidelines, the National Medical Commission’s regulatory architecture (which replaced the Medical Council of India in 2020), and the Digital Personal Data Protection Act, 2023 will continue to evolve.

For now, the cautious interpretation is the operational reality.

What this means for patients

In practical terms, an Indian patient receiving ADHD care under the current regime is likely to find:

• That tele-consultation is broadly available for evaluation, diagnosis, and non-stimulant management.
• That stimulant prescriptions require in-person visits, even for established patients on stable doses.
• That psychiatrists practising at substantial geographical distance from their patient often work in hybrid mode.
• That the regulatory situation may shift if the Guidelines are revised; this article is current as of its publication date and should be re-checked for material changes.

Patients with specific situations should ask the treating psychiatrist directly about how they handle remote-prescription questions. There is no national uniform practice.

Frequently asked questions

Can a psychiatrist diagnose ADHD by tele-consultation in India?

The 2020 Guidelines permit diagnosis by tele-consultation by a registered medical practitioner where appropriate. Whether a particular psychiatrist conducts a complete ADHD evaluation remotely is a clinical judgement.

Can methylphenidate be prescribed by tele-consultation?

No. Methylphenidate sits within the prohibited list of medicines for tele-prescription under the Guidelines. Stimulant prescriptions in current Indian practice require an in-person consultation.

Can atomoxetine be prescribed by tele-consultation?

Atomoxetine, dispensed under Schedule H, is generally treated as prescribable by tele-consultation, subject to the procedural requirements of the Guidelines.

Does the prohibition on tele-prescription of methylphenidate apply to follow-up refills?

The Guidelines, as drafted, do not distinguish between initiation and follow-up for the prohibited list. Most practising psychiatrists treat all stimulant prescriptions as in-person.

Where can I check whether the practitioner I am consulting is registered?

The National Medical Commission’s Indian Medical Register or the relevant State Medical Council register. The practitioner is also required by the Guidelines to share their registration number on request.

Sources

• The Telemedicine Practice Guidelines, 2020 (issued under the Indian Medical Council Act framework).
• The Drugs and Cosmetics Rules, 1945 (Schedule X).
• The Narcotic Drugs and Psychotropic Substances Act, 1985.
• National Medical Commission registration framework.
• Digital Personal Data Protection Act, 2023.